Vaccines (Aug 2024)

Development and Application of Automated Sandwich ELISA for Quantitating Residual dsRNA in mRNA Vaccines

  • David A. Holland,
  • Jillian Acevedo-Skrip,
  • Joshua Barton,
  • Rachel Thompson,
  • Amy Bowman,
  • Emily A. Dewar,
  • Danielle V. Miller,
  • Kaixi Zhao,
  • Andrew R. Swartz,
  • John W. Loughney

DOI
https://doi.org/10.3390/vaccines12080899
Journal volume & issue
Vol. 12, no. 8
p. 899

Abstract

Read online

The rise of mRNA as a novel vaccination strategy presents new opportunities to confront global disease. Double-stranded RNA (dsRNA) is an impurity byproduct of the in vitro transcription reaction used to manufacture mRNA that may affect the potency and safety of the mRNA vaccine in patients. Careful quantitation of dsRNA during manufacturing is critical to ensure that residual dsRNA is minimized in purified mRNA drug substances. In this work, we describe the development and implementation of a sandwich Enzyme-Linked Immunosorbent Assay (ELISA) to quantitate nanogram quantities of residual dsRNA contaminants in mRNA process intermediates using readily available commercial reagents. This sandwich ELISA developed in this study follows a standard protocol and can be easily adapted to most research laboratory environments. Additionally, a liquid handler coupled with an automated robotics system was utilized to increase assay throughput, improve precision, and reduce the analyst time requirement. The final automated sandwich ELISA was able to measure <10 ng/mL of dsRNA with a specificity for dsRNA over 2000-fold higher than mRNA, a variability of <15%, and a throughput of 72 samples per day.

Keywords